Research progress of late lumen enlargement after drug-coated balloon angioplasty for de novo coronary artery disease
-
摘要: 冠状动脉支架内再狭窄成为药物涂层球囊(DCB)的主要适应证后，DCB越来越多地作为其一线治疗方式。此外，更多的临床证据支持DCB在原位病变中的应用，尤其是小血管病变、高出血风险和心肌梗死等特殊患者群体。和药物洗脱支架相比，DCB的优势在于没有永久性金属支架的植入，同时，多项研究观察到DCB治疗冠状动脉原位病变后出现晚期管腔扩大现象，晚期管腔扩大的出现被认为有临床益处。本文就DCB治疗冠状动脉原位病变后的晚期管腔扩大现象的可能机制和影响因素作一综述。Abstract: Coronary in-stent restenosis(ISR) has become the main indication of the drug-coated balloon(DCB), DCB is increasingly used as a first-line treatment. In addition, more clinical evidence supports the application of DCB in de novo coronary lesions, especially in special patient groups such as small vessel disease, high bleeding risk, and myocardial infarction. Compared with drug-eluting stents, the advantage of DCB is that there is no permanent metal stent implantation. At the same time, many studies have observed the phenomenon of late lumen enlargement after DCB treatment of de novo coronary lesions. The emergence of late lumen enlargement is considered to be of clinical benefit. This article reviews the possible mechanisms and influencing factors of late lumen enlargement after DCB treatment of de novo coronary lesions.
-
-
[1] Tweet MS, Gulati R, Williamson EE, et al. Multimodality Imaging for Spontaneous Coronary Artery Dissection in Women[J]. JACC Cardiovasc Imaging, 2016, 9(4): 436-450. doi: 10.1016/j.jcmg.2016.01.009
[2] Mennuni MG, Pagnotta PA, Stefanini GG. Coronary Stents: The Impact of Technological Advances on Clinical Outcomes[J]. Ann Biomed Eng, 2016, 44(2): 488-496. doi: 10.1007/s10439-015-1399-z
[3] Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents[J]. J Am Coll Cardiol, 2011, 57(11): 1314-1322. doi: 10.1016/j.jacc.2011.01.011
[4] Siontis GC, Stefanini GG, Mavridis D, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis[J]. Lancet, 2015, 386(9994): 655-664. doi: 10.1016/S0140-6736(15)60657-2
[5] Giacoppo D, Alfonso F, Xu B, et al. Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials(DAEDALUS study)[J]. Eur Heart J, 2020, 41(38): 3715-3728. doi: 10.1093/eurheartj/ehz594
[6] Bajraktari G, Jashari H, Ibrahimi P, et al. Comparison of drug-eluting balloon versus drug-eluting stent treatment of drug-eluting stent in-stent restenosis: A meta-analysis of available evidence[J]. Int J Cardiol, 2016, 218: 126-135. doi: 10.1016/j.ijcard.2016.05.040
[7] 杨新越, 潘亮, 郑悠阳, 等. 药物涂层球囊在冠状动脉原位病变中的应用现状[J]. 临床心血管病杂志, 2021, 37(8): 695-699. doi: 10.13201/j.issn.1001-1439.2021.08.003
[8] Jeger RV, Farah A, Ohlow MA, et al. Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease(BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial[J]. Lancet, 2020, 396(10261): 1504-1510. doi: 10.1016/S0140-6736(20)32173-5
[9] Rissanen TT, Uskela S, Eränen J, et al. Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk(DEBUT): a single-blind, randomised, non-inferiority trial[J]. The Lancet, 2019, 394(10194): 230-239. doi: 10.1016/S0140-6736(19)31126-2
[10] Scheller B, Ohlow MA, Ewen S, et al. Bare metal or drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial infarction: the randomised PEPCAD NSTEMI trial[J]. EuroIntervention, 2020, 15(17): 1527-1533. doi: 10.4244/EIJ-D-19-00723
[11] 杨新越, 卢文杰, 王玺, 等. 药物涂层球囊治疗冠状动脉原位弥漫性病变的3年疗效分析[J]. 临床心血管病杂志, 2022, 38(8): 631-637. doi: 10.13201/j.issn.1001-1439.2022.08.007 https://lcxxg.whuhzzs.com/article/doi/10.13201/j.issn.1001-1439.2022.08.007
[12] Naganuma T, Latib A, Sgueglia GA, et al. A 2-year follow-up of a randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels the BELLO study[J]. Int J Cardiol, 2015, 184: 17-21. doi: 10.1016/j.ijcard.2015.01.080
[13] Yang X, Lu W, Pan L, et al. Long-term outcomes of drug-coated balloons in patients with diffuse coronary lesions[J]. Front Cardiovasc Med, 2022, 9: 935263. doi: 10.3389/fcvm.2022.935263
[14] Kleber FX, Schulz A, Waliszewski M, et al. Local paclitaxel induces late lumen enlargement in coronary arteries after balloon angioplasty[J]. Clin Res Cardiol, 2015, 104(3): 217-225. doi: 10.1007/s00392-014-0775-2
[15] Funatsu A, Nakamura S, Inoue N, et al. A multicenter randomized comparison of paclitaxel-coated balloon with plain balloon angioplasty in patients with small vessel disease[J]. Clin Res Cardiol, 2017, 106(10): 824-832. doi: 10.1007/s00392-017-1126-x
[16] 杨新越, 郑悠阳, 林立, 等. 原位冠状动脉弥漫性病变药物涂层球囊植入术后晚期管腔扩大的影响因素[J]. 山东医药, 2022, 62(7): 50-52. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYY202207013.htm
[17] Ann SH, Balbir Singh G, Lim KH, et al. Anatomical and Physiological Changes after Paclitaxel-Coated Balloon for Atherosclerotic De Novo Coronary Lesions: Serial IVUS-VH and FFR Study[J]. PLoS One, 2016, 11(1): e0147057. doi: 10.1371/journal.pone.0147057
[18] Jeger RV, Eccleshall S, Ahmad WAW, et al. Drug-Coated Balloons for Coronary Artery Disease Third Report of the International DCB Consensus Group[J]. JACC Cardiovasc Interv, 2020, 13(12): 1391-1402. doi: 10.1016/j.jcin.2020.02.043
[19] Park JJ, Chae IH, Cho YS, et al. The recanalization of chronic total occlusion leads to lumen area increase in distal reference segments in selected patients: an intravascular ultrasound study[J]. JACC Cardiovasc Interv, 2012, 5(8): 827-836. doi: 10.1016/j.jcin.2012.05.004
[20] Galassi AR, Tomasello SD, Crea F, et al. Transient impairment of vasomotion function after successful chronic total occlusion recanalization[J]. J Am Coll Cardiol, 2012, 59(8): 711-718. doi: 10.1016/j.jacc.2011.10.894
[21] Nestelberger T, Kaiser C, Jeger R. Drug-coated balloons in cardiovascular disease: benefits, challenges, and clinical applications[J]. Expert Opin Drug Deliv, 2020, 17(2): 201-211. doi: 10.1080/17425247.2020.1714590
[22] Scheller B, Fischer D, Clever YP, et al. Treatment of a coronary bifurcation lesion with drug-coated balloons: lumen enlargement and plaque modification after 6 months[J]. Clin Res Cardiol, 2013, 102(6): 469-472. doi: 10.1007/s00392-013-0556-3
[23] Speck U, Cremers B, Kelsch B, et al. Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel?[J]. Circ Cardiovasc Interv, 2012, 5(3): 392-400. doi: 10.1161/CIRCINTERVENTIONS.111.967794
[24] Gray WA, Granada JF. Drug-coated balloons for the prevention of vascular restenosis[J]. Circulation, 2010, 121(24): 2672-2680. doi: 10.1161/CIRCULATIONAHA.110.936922
[25] Her AY, Ann SH, Singh GB, et al. Serial Morphological Changes of Side-Branch Ostium after Paclitaxel-Coated Balloon Treatment of De Novo Coronary Lesions of Main Vessels[J]. Yonsei Med J, 2016, 57(3): 606-613. doi: 10.3349/ymj.2016.57.3.606
[26] Yamamoto T, Sawada T, Uzu K, et al. Possible mechanism of late lumen enlargement after treatment for de novo coronary lesions with drug-coated balloon[J]. Int J Cardiol, 2020, 321: 30-37. doi: 10.1016/j.ijcard.2020.07.028
[27] Escuer J, Schmidt AF, Peña E, et al. Mathematical modelling of endovascular drug delivery: Balloons versus stents[J]. Int J Pharm, 2022, 620: 121742. doi: 10.1016/j.ijpharm.2022.121742
[28] Weiss AJ, Lorente-Ros M, Correa A, et al. Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?[J]. Curr Atheroscler Rep, 2022, 24(9): 731-744. doi: 10.1007/s11883-022-01049-z
[29] Kuwabara K, Zen K, Yashige M, et al. Comparative Analysis of the Paclitaxel-Eluting Peripheral Igaki-Tamai Stent and the Drug-Free Igaki-Tamai Stent Using Optical Coherence Tomography and Histological Analysis in a Porcine Iliac Artery Model[J]. Circ J, 2020, 84(5): 799-805. doi: 10.1253/circj.CJ-20-0040
[30] Maslov M, Foianini S, Lovich M. Delivery of drugs, growth factors, genes and stem cells via intrapericardial, epicardial and intramyocardial routes for sustained local targeted therapy of myocardial disease[J]. Expert Opin Drug Deliv, 2017, 14(10): 1227-1239. doi: 10.1080/17425247.2017.1292249
[31] di Palma G, Sanchez-Jimenez EF, Lazar L, et al. Should paclitaxel be considered an old generation DCB? The limus era[J]. Rev Cardiovas Med, 2021, 22(4): 1323-1330. doi: 10.31083/j.rcm2204138
[32] Maranhão RC, Tavares ER, Padoveze AF, et al. Paclitaxel associated with cholesterol-rich nanoemulsions promotes atherosclerosis regression in the rabbit[J]. Atherosclerosis, 2008, 197(2): 959-966. doi: 10.1016/j.atherosclerosis.2007.12.051
[33] Giannopoulos S, Secemsky EA, Schneider PA, et al. Concomitant Drug Coated Balloon Angioplasty With Bail-Out Use of Eluvia Drug-Eluting Stent: Is There Any Downside to a Double Dose of Paclitaxel?[J]. J Invasive Cardiol, 2022, 34(6): E469-E476.
[34] Levin AD, Vukmirovic N, Hwang CW, et al. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel[J]. Proc Natl Acad Sci U S A, 2004, 101(25): 9463-9467. doi: 10.1073/pnas.0400918101
[35] Sogabe K, Koide M, Fukui K, et al. Optical coherence tomography analysis of late lumen enlargement after paclitaxel-coated balloon angioplasty for de-novo coronary artery disease[J]. Catheter Cardiovasc Interv, 2021, 98(1): E35-E42. doi: 10.1002/ccd.29069
[36] Hui L, Shin ES, Jun EJ, et al. Impact of Dissection after Drug-Coated Balloon Treatment of De Novo Coronary Lesions: Angiographic and Clinical Outcomes[J]. Yonsei Med J, 2020, 61(12): 1004-1012. doi: 10.3349/ymj.2020.61.12.1004
[37] Cappelletti A, Margonato A, Rosano G, et al. Short-and long-term evolution of unstented nonocclusive coronary dissection after coronary angioplasty[J]. J Am Coll Cardiol, 1999, 34(5): 1484-1488. doi: 10.1016/S0735-1097(99)00395-2
[38] Leimgruber PP, Roubin GS, Anderson HV, et al. Influence of intimal dissection on restenosis after successful coronary angioplasty[J]. Circulation, 1985, 72(3): 530-535. doi: 10.1161/01.CIR.72.3.530
[39] Cortese B, Silva Orrego P, Agostoni P, et al. Effect of Drug-Coated Balloons in Native Coronary Artery Disease Left With a Dissection[J]. JACC Cardiovasc Interv, 2015, 8(15): 2003-2009. doi: 10.1016/j.jcin.2015.08.029
[40] Paulo M, Sandoval J, Lennie V, et al. Combined use of OCT and IVUS in spontaneous coronary artery dissection[J]. JACC Cardiovasc Imaging, 2013, 6(7): 830-832. doi: 10.1016/j.jcmg.2013.02.010
[41] Onishi T, Onishi Y, Kobayashi I, et al. Late lumen enlargement after drug-coated balloon angioplasty for de novo coronary artery disease[J]. Cardiovasc Interv Ther, 2021, 36(3): 311-318. doi: 10.1007/s12928-020-00690-2
[42] Köln PJ, Scheller B, Liew HB, et al. Treatment of chronic total occlusions in native coronary arteries by drug-coated balloons without stenting-A feasibility and safety study[J]. Int J Cardiol, 2016, 225: 262-267. doi: 10.1016/j.ijcard.2016.09.105
[43] Togni M, Windecker S, Cocchia R, et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction[J]. J Am Coll Cardiol, 2005, 46(2): 231-236. doi: 10.1016/j.jacc.2005.01.062
-
计量
- 文章访问数: 1195
- PDF下载数: 487
- 施引文献: 0
下载: